FDA Warns Over Denigrating Biosimilars

Draft Guidance Seeks To Clamp Down On Efforts To Hinder Uptake

 
• By Derrick Gingery
Advertising
The FDA said accurate information comparing a biosimilar and its reference product could be considered misleading if offered in the wrong context • Source: Shutterstock

More from Biosimilars

More from Products